GLP-1減量薬：オゼンピック・ウゴービ徹底解説
クイックアンサー: GLP-1受容体作動薬（GLP-1 Receptor Agonists）であるセマグルチド（Semaglutide）は平均15-17%の体重減少を実現します。オゼンピック（Ozempic、注射用セマグルチド、最大1mg/週）は元々2型糖尿病用に承認され、ウゴービ（Wegovy、最大2.4mg/週）は減量専用に承認されています。作用機序：GLP-1ホルモンを模倣し、胃排出を遅延、満腹感を増加、食欲を抑制、インスリン感受性を改善します。STEP試験ではWegovy 2.4mg/週で平均約15%の体重減少が示されました。よくある副作用：悪心（約40%、通常徐々に軽減）、嘔吐、下痢、便秘。まれだが重篤なリスク：膵炎、胆嚢疾患。重要：投薬中止後に生活習慣を変えなければ、減量効果の約2/3が1年以内にリバウンドする可能性があります。
Disclaimer: この内容は情報提供のみを目的としており、医療アドバイスではありません。 免責事項全文.
How Do GLP-1 Medications Work for Weight Loss?
GLP-1 (glucagon-like peptide-1) receptor agonists represent the most significant advancement in obesity treatment in decades. These medications mimic a natural gut hormone that regulates appetite and blood sugar:
- Appetite suppression: GLP-1 acts on brain receptors in the hypothalamus to reduce hunger and increase satiety, leading to naturally reduced food intake of 20-30%
- Slowed gastric emptying: Food stays in the stomach longer, prolonging feelings of fullness after meals
- Improved insulin sensitivity: Originally developed for type 2 diabetes, these medications reduce insulin resistance and blood sugar spikes
- Reduced food reward: Emerging neuroimaging research suggests GLP-1 agonists decrease the brain's reward response to high-calorie foods
The currently available medications include:
- Semaglutide (Wegovy): FDA-approved for weight management at 2.4mg weekly injection. Also sold as Ozempic (1-2mg) for diabetes.
- Tirzepatide (Mounjaro/Zepbound): A dual GIP/GLP-1 agonist showing even greater weight loss in trials (up to 22.5% body weight).
- Liraglutide (Saxenda): An older GLP-1 agonist with more modest results (5-8% weight loss).
What Results Can You Expect from GLP-1 Medications?
Clinical trial data provides a clear picture of expected outcomes:
- STEP 1 trial (NEJM, 2021): Semaglutide 2.4mg produced average weight loss of 14.9% (vs. 2.4% placebo) over 68 weeks in adults with obesity. One-third of participants lost 20%+ body weight.
- SURMOUNT-1 trial (NEJM, 2022): Tirzepatide at highest dose produced average 22.5% weight loss over 72 weeks — approaching bariatric surgery results.
- Cardiovascular benefits: The SELECT trial (2023) showed semaglutide reduced major cardiovascular events by 20% in people with obesity and established heart disease.
Important caveats:
- Weight regain: The STEP 1 extension study found participants regained two-thirds of lost weight within 1 year of stopping the medication
- Muscle loss: Approximately 25-40% of weight lost is lean mass (muscle), which is a concern for long-term metabolic health. Resistance training and adequate protein (1.6g+/kg) are essential adjuncts.
If you are prescribed a GLP-1 medication, use WAYJET's Prescription Analyzer to verify dosing guidelines and check for interactions with your other medications.
What Are the Side Effects and Risks?
GLP-1 medications have a generally well-established safety profile, but side effects are common, especially during dose escalation:
- Gastrointestinal (most common): Nausea (40-44%), diarrhea (30%), vomiting (24%), constipation (24%). Usually mild-to-moderate and improve over 4-8 weeks.
- Gallbladder issues: Rapid weight loss increases gallstone risk. The STEP trials reported cholelithiasis in 2-3% of semaglutide users vs. 1% placebo.
- Pancreatitis: Rare (0.1-0.3%) but serious. Seek immediate care for severe abdominal pain.
- Thyroid C-cell tumors: Observed in rodent studies at high doses. Contraindicated in patients with personal or family history of medullary thyroid carcinoma (MTC) or MEN2 syndrome.
Who should NOT take GLP-1 medications:
- Personal/family history of medullary thyroid cancer or MEN2
- History of pancreatitis
- Pregnant or planning to become pregnant (stop at least 2 months before conception for semaglutide)
- History of severe gastrointestinal disease
Cost remains a significant barrier: without insurance, Wegovy costs approximately $1,300-1,600 per month. Coverage varies significantly by insurer and employer plan.
よくある質問
What is the difference between Ozempic and Wegovy?
Both contain semaglutide but differ in approved use and dosing. Ozempic is FDA-approved for type 2 diabetes (max dose 2mg weekly), while Wegovy is approved for weight management (dose 2.4mg weekly). Wegovy was specifically studied in obesity trials. Using Ozempic off-label for weight loss is common but may not be covered by insurance for that purpose.
Do you have to take GLP-1 medications forever?
Current evidence suggests most people regain weight after discontinuation. The STEP 4 trial showed continued weight loss with ongoing treatment vs. significant regain when switched to placebo. Long-term use appears necessary for sustained results, similar to other chronic disease medications. Ongoing research is exploring whether lifestyle modifications during treatment can improve post-cessation outcomes.
Can GLP-1 medications cause hair loss?
Hair loss (telogen effluvium) has been reported in clinical trials, affecting about 3-5% of semaglutide users. This is likely triggered by rapid weight loss rather than the medication itself — any significant weight loss can cause temporary shedding. Hair typically regrows once weight stabilizes. Adequate protein and micronutrient intake may help minimize this side effect.
関連記事
--- WAYJET分析 ---